Zepbound — Eli Lilly’s latest weight management medication — received approval from the Food and Drug Administration this week for use in adults who are obese or are overweight with at least one weight-related condition.
If Zepbound sounds familiar, that’s because it is: The base drug is tirzepatide, which is the same as Eli Lilly’s Mounjaro. The difference between Zepbound and Mounjaro is that Zepbound has been approved specifically for weight management, while Mounjaro’s intended use is for the management of type 2 diabetes. Until now, doctors prescribing the drug for weight loss have been doing so off-label.
